MNLO Menlo Therapeutics Inc.

7.33
+0.05  (+1%)
Previous Close 7.28
Open 7.25
Price To Book 1.31
Market Cap 170482489
Shares 23,258,184
Volume 37,047
Short Ratio
Av. Daily Volume 106,671

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released December 10, 2018 - primary endpoint met.
Serlopitant
Pruritus associated with psoriasis
Phase 3 data due 1H 2020.
Serlopitant
Pruritus associated with prurigo nodularis
Phase 2 data released October 8, 2018. Endpoints not met.
Serlopitant
Refractory chronic cough
Phase 2 data released April 9, 2018. Endpoints not met.
Serlopitant
Pruritus associated with atopic dermatitis
Phase 2 data due mid-2020.
Serlopitant
Chronic pruritus of unknown origin

Latest News

  1. Consider These 3 Falling Knives
  2. EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
  3. Menlo Therapeutics Announces Publication of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis
  4. Menlo Therapeutics Announces New Board Member Elisabeth Sandoval
  5. Menlo Therapeutics to Present at the 31st Annual ROTH Conference
  6. Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  7. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
  8. Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting
  9. Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics — Future Expectations, Projections Moving into 2019
  10. Menlo Therapeutics’ Serlopitant Granted Breakthrough Therapy Designation by FDA for the Treatment of Pruritus Associated with Prurigo Nodularis
  11. Lawsuit for Investors in NASDAQ: MNLO shares against Menlo Therapeutics Inc. announced by Shareholders Foundation
  12. What does Menlo Therapeutics Inc.’s (NASDAQ:MNLO) Balance Sheet Tell Us About Its Future?
  13. Lawsuit for Investors in shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) announced by Shareholders Foundation
  14. Menlo Therapeutics Inc. (MNLO): Are Hedge Funds Right About This Stock?
  15. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
  16. Robbins Arroyo LLP: Menlo Therapeutics Inc. (MNLO) Misled Shareholders According to Class Action
  17. Market Trends Toward New Normal in Apptio, Menlo Therapeutics, Tanger Factory Outlet Centers, Cedar Realty Trust, Toll Brothers, and II-VI — Emerging Consolidated Expectations, Analyst Ratings
  18. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Inc.
  19. Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis